# UK Organ On Chip Market

> UK Organ-on-Chip Market Research Report: Size, Share, Trend Analysis By Organ Type (Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, Human-on-Chip), By Applications (Drug Discovery, Toxicology Research, Others) andBy End-User (Pharmaceutical Companies, Research Organizations, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.5%
- **2024:** $ 20.53 Million
- **2025:** $ 21.86 Million
- **2035:** $ 41.05 Million
- **Key Players:** Emulate Inc (US), Mimetas (NL), TissUse (DE), Organovo Holdings Inc (US), Synlogic Inc (US), Hesperos Inc (US), InSphero AG (CH), Reinnervate Ltd (GB)

**Report ID:** MRFR/MED/49549-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/uk-organ-on-chip-market-51306

---

## Market Summary

## **UK Organ-on-Chip Market Overview**

As per MRFR analysis, the UK Organ-on-Chip Market Size was estimated at 4.04 (USD Million) in 2023.The UK Organ-on-Chip Market Industry is expected to grow from 4.51(USD Million) in 2024 to 19.23 (USD Million) by 2035. The UK Organ-on-Chip Market CAGR (growth rate) is expected to be around 14.084% during the forecast period (2025 - 2035).

## **Key UK Organ-on-Chip Market Trends Highlighted**

The UK Organ-On-Chip market is changing along with the advancements in biotechnology, and there is a strong need for improving drug testing methods. UK healthcare considers new therapy technologies especially impactful along with many schemes to improve patient care and research. Because of this, there is greater financial support towards the R&D of organ-on-chip technologies, which is now one of the leading boosters in the country. There is also increasing demand for humane and ethical systems to replace animal testing with organ-on-chip systems because ethics and efficiency as drug testing candidates concerns human body representation.

Collaboration between academic institutions and private companies for fostering innovation in the UK is an opportunity waiting to be tackled. In this regard, The UK has a robust life sciences ecosystem and can be supported by several leading universities and research centers. Also, there is an increasing focus on personalized medicine which can be done organ-on-chip devices that would tailor the treatment to the individual patient. UK support for organ-on-chip products regulatory support has surged recently.

These technologies are increasingly being recognized by UK regulatory agencies for drug development and safety testing, and there is growing support for these innovations to be fast-tracked for market entry.

This progress will most probably lead to faster incorporation of organ-on-chip technology into more testing processes like drug discovery and disease modeling. With all of this going on, the UK stands as a perfect candidate to become the main player in the organ-on-chip industry with the right conditions for development and collaboration.

## **UK Organ-on-Chip Market Drivers**

### **Increasing Investment in Research and Development**

Investment in Research and Development (R&D) within the UK Organ-on-Chip Market Industry is witnessing significant growth driven by a surge in funding from both public and private sectors. The UK government has committed to substantial funding for innovative health technologies, with initiatives like the UK Research and Innovation (UKRI) allocating over 1 billion GBP for health-related innovation since last year. Additionally, major pharmaceutical companies such as GlaxoSmithKline and AstraZeneca are actively investing in organ-on-chip technologies, focusing on enhancing drug discovery and safety testing processes.

This trend has resulted in a sophisticated ecosystem conducive to advancements in organ-on-chip technology, where localized R&D efforts are expected to lead to the development of optimized platforms for real-time physiological and pathological studies. The expected growth in this sector of around 14.08% compound annual growth rate (CAGR) further highlights the robust investment trajectory observed in the UK.

### **Rising Demand for Personalized Medicine**

The UK Organ-on-Chip Market Industry is experiencing an increase in demand for personalized medicine, notably as healthcare providers and patients alike seek tailored therapeutic solutions. The National Health Service (NHS) has recognized the need for a shift toward personalized treatment approaches, with initiatives aimed at providing patients with drugs tailored to their unique genetic profiles. This personalized approach not only enhances treatment efficacy but also minimizes adverse drug reactions, thus reducing healthcare costs in the long run.

As such, organ-on-chip platforms are being developed to mimic individual patients’ physiological conditions, thereby providing invaluable data to guide personalized therapies. The anticipated growth in the UK Organ-on-Chip Market Industry aligns with these trends as more healthcare providers and organizations adopt these innovative technologies.

### **Growing Regulatory Support**

Regulatory bodies in the UK are increasingly supportive of the adoption of organ-on-chip technologies, fostering an environment conducive to market growth. Agencies like the Medicines and Healthcare products Regulatory Agency (MHRA) are advocating for the implementation of advanced technologies in drug testing and safety assessments. New guidelines are being formulated that recognize the validity and utility of organ-on-chip platforms in regulatory submissions, which serve to accelerate the approval process for new therapeutics.

For instance, the UK's commitment to promoting alternative testing methods is reflected in its alignment with the 3Rs principle (Replacement, Reduction, Refinement), emphasizing the necessity for innovative and humane approaches to research. Such support structures are expected to create a favorable business climate for companies operating in the UK Organ-on-Chip Market Industry, thus propelling growth in this segment.

## **UK Organ-on-Chip Market Segment Insights**

### **Organ-on-Chip Market Organ Type Insights**

The UK Organ-on-Chip Market is witnessing a transformative phase, particularly within the Organ Type segment, which encompasses innovative technologies such as Lung-on-Chip, Heart-on-Chip, Liver-on-Chip, Intestine-on-Chip, Kidney-on-Chip, and Human-on-Chip models. Each of these platforms plays a vital role in revolutionizing biological studies and pharmaceutical testing by allowing researchers to simulate human organ functions in vitro, leading to more accurate drug responses and disease modeling. The Lung-on-Chip model is particularly significant as it helps in studying respiratory diseases and enables researchers to examine drug effects against lung conditions such as asthma and chronic obstructive pulmonary disease.

This aspect is particularly relevant for the UK, where respiratory health has been a point of focus for public health improvements under government initiatives.

The Heart-on-Chip segment is also crucial, serving to investigate cardiac diseases and evaluate the safety of numerous pharmaceuticals that could impact heart function. Given the growing concern around cardiovascular diseases within the UK, this model notably supports the trend of personalized medicine by facilitating precise drug testing and development. The Liver-on-Chip technology stands out in the context of drug metabolism and toxicity studies, addressing the rising need for safer drug design as the pharmaceutical sector comes under scrutiny for adverse drug reactions.

Considering the prevalence of liver-related disorders in the UK population, this model fosters advancements in understanding liver functions and pathologies.

Moreover, the Intestine-on-Chip model is emerging as a foundational platform for gut microbiome studies, contributing significantly to our comprehension of gastrointestinal diseases and their relation to systemic health. This has a direct linkage to public health policies focusing on improving dietary health and managing conditions like inflammatory bowel disease, thus gaining importance in the UK healthcare conversation. The Kidney-on-Chip platform is essential for renal research, particularly against the backdrop of increasing rates of chronic kidney disease in the UK scene, making it a critical area of investigation for nephrology and drug development.

The Human-on-Chip design is a holistic approach, integrating multiple organ functionalities that can represent the complexities of a whole human system. This model is vital for understanding multi-organ interactions and advancing disease modeling, offering a more comprehensive platform for drug testing and elucidating pathophysiological processes. Overall, the segmentation within the UK Organ-on-Chip Market presents unique opportunities to address contemporary healthcare challenges, supported by a robust foundation of government-backed healthcare initiatives aimed at improving health outcomes through innovative technologies.

The ongoing development in each of these organ models highlights a shift towards a more integrated and advanced understanding of human biology, emphasizing significant growth potential and influence in the UK healthcare landscape.

### **Organ-on-Chip Market Application Insights**

The Application segment of the UK Organ-on-Chip Market plays a crucial role in developing innovative solutions for the pharmaceutical and biotechnology industries. This segment predominantly focuses on Drug Discovery and Toxicology Research, which are essential for evaluating drug efficacy and safety. The growing demand for more accurate preclinical testing models drives the need for Organ-on-Chip technology, as it effectively mimics human organ functions, significantly reducing the reliance on animal testing. Drug Discovery is particularly vital for the UK, which boasts a strong pharmaceutical sector, making the integration of microfluidic technologies increasingly important.

Toxicology Research also stands out, given the stringent regulatory requirements in the UK aimed at ensuring public safety and environmental protection. Moreover, as the industry continues to evolve, there are ample opportunities in both academia and the private sector to leverage Organ-on-Chip technology for advancements in Personalized Medicine and precision therapeutics. The UK government supports innovation in the biotech field, further enhancing the growth potential of the Organ-on-Chip market, characterized by robust relationships between industry, academia, and regulatory bodies.

This collaborative environment fosters the development of advanced models that can transform drug testing processes while addressing the growing demands of healthcare stakeholders.

### **Organ-on-Chip Market End-User Insights**

The UK Organ-on-Chip Market, a rapidly evolving sector, showcases significant engagement from various end-users, including Pharmaceutical Companies, Research Organizations, and Other entities. Pharmaceutical Companies play a crucial role in leveraging organ-on-chip technologies for drug testing and development, enabling them to enhance the efficiency of therapeutic interventions while minimizing costs and time. These companies are increasingly adopting innovative in vitro models that replicate human physiology to better predict drug reactions, thus transforming their Research and Development processes.

Research Organizations also represent a vital component of the UK Organ-on-Chip Market, as they investigate novel applications and refine organ-on-chip systems for diverse biomedical applications. Their contributions not only advance scientific understanding but also promote collaborations with leading manufacturers and academic institutions to drive innovation. Additionally, Other end-users, encompassing academic institutions and regulatory bodies, are crucial for advancing the regulatory frameworks and guidelines governing the application of organ-on-chip technologies. Through these collaborations, the market experiences growth driven by the necessity for more accurate, ethical, and cost-effective alternatives to traditional testing methods.

Overall, the engagement of these end-users underpins the dynamic evolution of the UK Organ-on-Chip Market, fostering advancements that promise significant impacts across healthcare and pharmaceutical landscapes.

## **UK Organ-on-Chip Market Key Players and Competitive Insights**

The UK Organ-on-Chip Market is gaining substantial traction, reflecting a growing interest in advanced in vitro models for drug development and disease modeling. This innovative technology simulates human organs and physiological responses, providing researchers with a powerful tool for testing pharmacological responses and understanding disease mechanisms. Several key players have emerged in this dynamic sector, contributing to a landscape marked by competition and collaboration. As organizations continue to invest in developmental research and strategic partnerships, understanding market potentials and player roles becomes critical for future advancements.

The insights into competitive positioning reveal how businesses are leveraging technological innovations and regulatory environments to enhance their market presence and operational capabilities.

Mimetas has established a significant presence in the UK Organ-on-Chip Market, owing to its advanced microfluidic organ-on-chip technology designed for high-throughput screening and personalized medicine. The company specializes in organoid models that closely mimic physiological conditions, enabling researchers to gain better insights into drug efficacy and toxicity. Mimetas' strengths lie in its proprietary technology platforms that integrate seamless workflows, allowing for rapid testing and evaluation while minimizing the time and cost involved in traditional methods.

By offering versatile solutions that cater to various applications, Mimetas not only enhances its market appeal but also positions itself as a leader in innovative organ-on-chip solutions. Its commitment to research collaboration in the UK further solidifies its foothold in the market, enabling advancements in biomedical research and pharmaceutical development.

Hesperos, with its foothold in the UK Organ-on-Chip Market, operates at the intersection of innovation and healthcare research through its bioengineered human models. The company’s key products include advanced organ-on-chip systems designed to replicate human organ function for drug screening, disease modeling, and toxicology assessments. Hesperos' strengths are rooted in its state-of-the-art technology that utilizes human cells to create physiologically relevant models, enhancing the accuracy of drug testing outcomes. Additionally, Hesperos has been active in forging strategic collaborations and partnerships to bolster its capabilities and reach within the UK.

The company actively pursues mergers and acquisitions to accelerate its growth trajectory and broaden its service offerings in the rapidly evolving landscape of organ-on-chip technology. Through these initiatives, Hesperos not only solidifies its competitive edge but also contributes to the ongoing development of more effective and safer therapeutic options.

### **Key Companies in the UK Organ-on-Chip Market Include**

## **UK Organ-on-Chip Market Industry Developments**

The UK Organ-on-Chip Market has continued to experience significant developments recently. Companies like Mimetas and Hesperos are advancing their platforms for high-throughput drug testing, focusing on creating more accurate disease models. In July 2023, TissUse announced a partnership with Regenhu to enhance tissue engineering workflows, further validating collaborations across the sector. Acelity has contributed to advancing wound care applications within the Organ-on-Chip context. Market valuations have seen an upswing, with Biolife Solutions noting a substantial increase in demand for its biopreservation products utilized in Organ-on-Chip technologies, reflecting a heightened interest in innovative healthcare solutions.

Emulate is pushing boundaries with its latest organ models, gaining traction among pharmaceutical companies for drug discovery. The last couple of years have also seen major milestones, such as Organovo's increased focus on commercialization strategies in September 2022, alongside Stratec's advancements in automated systems for Organ-on-Chip platforms. Current outlooks suggest robust growth, propelled by rising investment and government support for biotechnology initiatives in the UK.

## **UK Organ-on-Chip Market Segmentation Insights**

### **Organ-on-Chip Market Organ Type Outlook**

### **Organ-on-Chip Market Application Outlook**

### **Organ-on-Chip Market End-User Outlook**

- Pharmaceutical Companies
- Research Organizations
- Others

## Market Drivers

### Growing Awareness of Ethical Concerns

Ethical considerations surrounding animal testing are increasingly influencing the organ on-chip market. As public awareness of animal welfare issues rises, there is a growing demand for alternative testing methods that do not rely on animal models. The organ on-chip technology presents a viable solution, offering a more humane approach to drug testing and development. This shift in consumer sentiment is prompting pharmaceutical companies and research institutions in the UK to adopt organ-on-chip systems as part of their testing protocols. The organ on-chip market is likely to benefit from this trend, as stakeholders seek to align their practices with ethical standards. Furthermore, regulatory bodies are beginning to recognize the potential of these technologies, which may lead to more favorable guidelines and support for their adoption. This evolving landscape suggests a promising future for the organ on-chip market as it aligns with societal values.

### Rising Demand for Personalized Medicine

The organ on-chip market is experiencing a notable surge in demand for personalized medicine solutions. As healthcare shifts towards tailored treatments, the need for advanced models that mimic human physiology becomes critical. This market driver is underscored by the increasing prevalence of chronic diseases in the UK, which necessitates innovative drug testing and development methods. The organ on-chip technology offers a promising alternative to traditional animal testing, providing more accurate predictions of human responses. According to recent estimates, the organ on-chip market is projected to grow at a CAGR of approximately 25% over the next five years, reflecting the growing interest in personalized therapeutic approaches. This trend indicates a significant opportunity for stakeholders in the organ on-chip market to develop solutions that cater to the specific needs of patients, thereby enhancing treatment efficacy and safety.

### Increased Investment in Biotech Research

Investment in biotechnology research is a pivotal driver for the organ on-chip market. The UK government and private sector are increasingly allocating funds to support innovative research initiatives aimed at developing advanced organ-on-chip technologies. This influx of capital is expected to accelerate the development of sophisticated models that can replicate human organ functions more accurately. Recent reports suggest that the UK biotech sector has seen an investment increase of over £1 billion in the last year alone, with a significant portion directed towards organ-on-chip research. This financial backing not only fosters innovation but also encourages collaboration between academic institutions and industry players, thereby enhancing the overall growth of the organ on-chip market. As research progresses, the potential applications of these technologies in drug discovery and disease modeling are likely to expand, further driving market demand.

### Advancements in Microfabrication Techniques

The organ on-chip market is being propelled by advancements in microfabrication techniques, which enable the creation of more complex and functional organ models. Innovations in materials science and engineering are allowing researchers to develop chips that closely mimic the architecture and functionality of human organs. These advancements are crucial for enhancing the predictive power of organ-on-chip systems in drug testing and disease modeling. As microfabrication technologies continue to evolve, the organ on-chip market is expected to expand, with new applications emerging in areas such as toxicology and regenerative medicine. The integration of these advanced techniques is likely to improve the reliability and reproducibility of organ-on-chip experiments, thereby attracting more researchers and companies to invest in this technology. This trend indicates a robust growth trajectory for the organ on-chip market in the coming years.

### Regulatory Changes Favoring Innovative Technologies

Regulatory changes in the UK are increasingly favoring the adoption of innovative technologies, including organ-on-chip systems. As regulatory agencies recognize the limitations of traditional testing methods, there is a growing push towards integrating advanced technologies that can provide more reliable data. This shift is likely to create a more conducive environment for the organ on-chip market, as companies seek to comply with evolving regulations while enhancing their research capabilities. Recent initiatives by UK regulatory bodies to streamline approval processes for alternative testing methods suggest a positive outlook for the organ on-chip market. By facilitating the entry of these technologies into the market, regulatory changes may accelerate the development and commercialization of organ-on-chip solutions, ultimately benefiting both researchers and patients.

## Future Outlook

The [Organ on chip Market](https://www.marketresearchfuture.com/reports/organ-on-chip-market-8498) is projected to grow at a 6.5% CAGR from 2025 to 2035, driven by advancements in biotechnology, regulatory support, and increasing demand for personalized medicine.

**New opportunities:**

- Development of customizable organ-on-chip platforms for specific disease models. Partnerships with pharmaceutical companies for drug testing applications. Integration of AI for predictive analytics in organ-on-chip systems.

By 2035, the organ on-chip market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Organ Type: Lung-on-Chip (Largest) vs. Heart-on-Chip (Fastest-Growing)

In the UK organ on-chip market, Lung-on-Chip holds the largest market share due to its substantial applications in drug testing and disease modeling. It is followed by Heart-on-Chip, which while smaller in share, is rapidly gaining traction as research focuses on cardiovascular diseases increases. Additionally, other organ types like Liver-on-Chip and Kidney-on-Chip are also significant players, but they do not match the growth pace of Heart-on-Chip.

The growth trends for this segment indicate a notable shift towards leveraging organ-on-chip technology for personalized medicine and toxicity testing. The increasing demand for efficient and ethical alternatives to animal testing is a key driver. Furthermore, advancements in biosensing technologies and the need for improved drug development processes are propelling the adoption of various organ types, particularly enhancing the position of the Heart-on-Chip as an emerging favorite in research and clinical applications.

Lung-on-Chip (Dominant) vs. Heart-on-Chip (Emerging)

Lung-on-Chip represents a dominant force in the UK organ on-chip market due to its extensive utilization in respiratory disease research and pharmaceutical testing, allowing for the recreation of complex lung environments. Its established presence provides a strong competitive advantage, as it meets the specific needs of researchers and developers focused on respiratory ailments. On the other hand, Heart-on-Chip, despite being labeled as emerging, has witnessed rapid advancements in engineering heart tissue models that mimic physiological heart functions. This organ type is supported by increasing investments and a growing focus on cardiovascular health, positioning it for significant growth in the near future.

### By Application: Drug Discovery (Largest) vs. Toxicology Research (Fastest-Growing)

In the UK organ on-chip market, the 'Drug Discovery' segment holds the largest share, accounting for a significant portion of the overall application landscape. This dominance is driven by the increasing demand for innovative drug development techniques and the growing trend of personalized medicine, where organ-on-chip technology plays a crucial role in simulating human responses effectively.

On the other hand, the 'Toxicology Research' segment is identified as the fastest-growing area. This growth is fuelled by escalating regulatory requirements and a shift towards more humane and efficient testing methods. Organizations are increasingly adopting organ-on-chip systems to meet these demands, which bodes well for the expansion of this segment in the coming years.

Drug Discovery (Dominant) vs. Toxicology Research (Emerging)

The 'Drug Discovery' segment is characterized by its significant role in enhancing the efficiency and accuracy of drug testing processes. It leverages organ-on-chip technology to provide realistic human tissue models, thus enabling researchers to observe drug interactions in ways traditional methods cannot replicate. Conversely, the 'Toxicology Research' segment, while emerging, is rapidly gaining traction as it offers innovative alternatives to animal testing. This segment is increasingly being viewed as an essential component in the drug development pipeline, driven by the need for ethical and scientifically valid testing methods.

### By End-User: Pharmaceutical Companies (Largest) vs. Research Organizations (Fastest-Growing)

In the UK organ on-chip market, pharmaceutical companies hold the largest share among end-users, reflecting their substantial investment in innovative solutions for drug development and toxicity testing. This sector utilizes organ-on-chip technologies to accelerate research processes, enhance efficiency, and reduce reliance on traditional animal testing. Conversely, research organizations, while currently smaller in market share, are rapidly expanding their use of these technologies to drive academic research and exploratory studies.

The growth trends within the end-user segment are highly influenced by advancements in technology and a rising demand for more effective drug testing methods. Research organizations are increasingly adopting organ-on-chip solutions due to their ability to provide precise and reliable data, thus propelling their growth. Moreover, the collaborative initiatives between pharmaceutical companies and research institutions further stimulate innovation and market expansion, establishing new standards for biological research and development.

Pharmaceutical Companies (Dominant) vs. Research Organizations (Emerging)

The pharmaceutical companies segment is characterized by its significant investment in organ-on-chip technologies, aimed at revolutionizing drug discovery and development processes. This dominance is attributed to their need for more efficient testing methods and a pressing requirement to comply with stringent regulatory standards. On the other hand, research organizations represent an emerging segment that is increasingly adopting organ-on-chip technologies for a range of academic purposes. Their focus on exploratory research and cutting-edge scientific inquiry positions them as valuable partners to pharmaceutical companies, facilitating collaborative projects that enhance the overall development and application of these innovative systems. As these organizations embrace organ-on-chip methodologies, they contribute to the growing acknowledgment of these technologies within the broader scientific community.

## Competitive Benchmarking

The organ on-chip market is currently characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for more efficient drug testing methods. Key players such as Emulate Inc (US), Mimetas (NL), and TissUse (DE) are at the forefront, each adopting distinct strategies to enhance their market positioning. Emulate Inc (US) focuses on innovation through the development of advanced organ-on-chip platforms that mimic human physiology, thereby improving the accuracy of drug testing. Meanwhile, Mimetas (NL) emphasizes partnerships with pharmaceutical companies to expand its reach and application of its organ-on-chip technology, which appears to be a strategic move to solidify its market presence. TissUse (DE) is also notable for its commitment to regional expansion, particularly in Europe, which suggests a strategy aimed at capturing a larger share of the growing demand for organ-on-chip solutions.The business tactics employed by these companies reflect a moderately fragmented market structure, where localized manufacturing and supply chain optimization are becoming increasingly vital. The collective influence of these key players indicates a competitive environment that is not only shaped by technological advancements but also by strategic collaborations and partnerships that enhance operational capabilities. This fragmentation allows for a diverse range of innovations, although it also necessitates a keen focus on efficiency and cost-effectiveness to maintain competitive advantage.

In October  Emulate Inc (US) announced a collaboration with a leading pharmaceutical company to develop a new organ-on-chip model that simulates the human liver. This strategic partnership is likely to enhance Emulate's product offerings and could significantly accelerate the drug development process, thereby positioning the company as a leader in the market. The implications of this collaboration suggest a potential shift in how drug testing is conducted, moving towards more personalized and accurate methodologies.

In September  Mimetas (NL) launched a new organ-on-chip platform designed specifically for cancer research, which could revolutionize the way oncological therapies are tested. This innovation not only underscores Mimetas's commitment to addressing critical healthcare challenges but also highlights its strategic focus on niche markets within the organ-on-chip sector. The introduction of this platform may attract significant interest from research institutions and pharmaceutical companies, further solidifying Mimetas's competitive edge.

In August  TissUse (DE) secured a substantial investment to enhance its manufacturing capabilities, which is indicative of its strategy to scale operations and meet the increasing demand for organ-on-chip technologies. This investment is expected to bolster TissUse's production efficiency and expand its product line, thereby enhancing its competitive positioning in the market. The focus on scaling operations aligns with the broader trend of companies seeking to optimize their supply chains in response to growing market demands.

As of November  the organ on-chip market is witnessing trends that emphasize digitalization, sustainability, and the integration of artificial intelligence. These trends are reshaping the competitive landscape, as companies increasingly seek strategic alliances to leverage technological advancements and enhance their product offerings. The shift from price-based competition to a focus on innovation and technology is becoming evident, suggesting that future competitive differentiation will hinge on the ability to deliver reliable, cutting-edge solutions that meet the evolving needs of the healthcare sector.

## Recent News & Developments

The UK Organ-on-Chip Market has continued to experience significant developments recently. Companies like Mimetas and Hesperos are advancing their platforms for high-throughput drug testing, focusing on creating more accurate disease models. In July 2023, TissUse announced a partnership with Regenhu to enhance tissue engineering workflows, further validating collaborations across the sector. Acelity has contributed to advancing wound care applications within the Organ-on-Chip context. Market valuations have seen an upswing, with Biolife Solutions noting a substantial increase in demand for its biopreservation products utilized in Organ-on-Chip technologies, reflecting a heightened interest in innovative healthcare solutions.

Emulate is pushing boundaries with its latest organ models, gaining traction among pharmaceutical companies for drug discovery. The last couple of years have also seen major milestones, such as Organovo's increased focus on commercialization strategies in September 2022, alongside Stratec's advancements in automated systems for Organ-on-Chip platforms. Current outlooks suggest robust growth, propelled by rising investment and government support for biotechnology initiatives in the UK.

## Report Scope

| MARKET SIZE 2024 | 20.53(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 21.86(USD Million) |
| MARKET SIZE 2035 | 41.05(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.5% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Emulate Inc (US), Mimetas (NL), TissUse (DE), Organovo Holdings Inc (US), Synlogic Inc (US), Hesperos Inc (US), InSphero AG (CH), Reinnervate Ltd (GB) |
| Segments Covered | Organ Type, Application, End-User |
| Key Market Opportunities | Advancements in organ-on-chip technology enhance drug testing efficiency and regulatory compliance in the UK. |
| Key Market Dynamics | Rising demand for organ-on-chip technologies driven by regulatory shifts and advancements in personalized medicine. |
| Countries Covered | UK |

## Frequently Asked Questions

**Q: What was the market valuation of the UK organ on-chip market in 2024?**
A: The market valuation was $20.53 Million in 2024.

**Q: What is the projected market valuation for the UK organ on-chip market by 2035?**
A: The projected valuation for 2035 is $41.05 Million.

**Q: What is the expected CAGR for the UK organ on-chip market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.5% during the forecast period 2025 - 2035.

**Q: Which organ-on-chip segments are expected to show significant growth?**
A: Segments such as Lung-on-Chip and Liver-on-Chip are expected to show significant growth, with valuations projected at $7.0 Million and $8.0 Million respectively by 2035.

**Q: Who are the key players in the UK organ on-chip market?**
A: Key players include Emulate Inc, Mimetas, TissUse, Organovo Holdings Inc, Synlogic Inc, Hesperos Inc, InSphero AG, and Reinnervate Ltd.

**Q: What applications are driving the UK organ on-chip market?**
A: Applications such as Drug Discovery and Toxicology Research are driving the market, with projected valuations of $16.25 Million and $14.25 Million respectively by 2035.

**Q: What is the expected market size for the Kidney-on-Chip segment by 2035?**
A: The expected market size for the Kidney-on-Chip segment is projected to reach $6.0 Million by 2035.

**Q: How do end-user segments contribute to the UK organ on-chip market?**
A: End-user segments like Pharmaceutical Companies are projected to contribute $20.52 Million by 2035, indicating strong demand.

**Q: What is the projected valuation for the Intestine-on-Chip segment by 2035?**
A: The projected valuation for the Intestine-on-Chip segment is expected to reach $4.0 Million by 2035.

**Q: What trends are influencing the growth of the UK organ on-chip market?**
A: Trends in personalized medicine and advanced drug testing methodologies appear to be influencing the growth of the market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-organ-on-chip-market-51306*